Clinical significance of the uPA system in gastric cancer with peritoneal metastasis

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Ding, Youcheng ^a   Zhang, Hui ^a   Zhong, Mingan ^a   Zhou, Zhuqing ^a   Zhuang, Zhixiang ^a   Yin, Hua ^a   Wang, Xujing ^a   Zhu, Zhenggang ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ELISA; Gastric cancer; Peritoneal metastasis; RT PCR; UPA system

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA;

ADENOCARCINOMA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLLOID CARCINOMA; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MESOTHELIUM CELL; PERITONEUM METASTASIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNET RING CARCINOMA; STOMACH CANCER; ADULT; AGED; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; STOMACH TUMOR; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER; STOMACH NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84883072532     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-28     Document Type: Article

References (30)

1. Incidence and mortality of gastric cancer in China. Yang L, World J Gastroenterol 2006 12 17 16440411
2. Recurrence following curative resection for gastric carcinoma. Yoo C, Noh S, Shin D, Choi S, Min J, British J Surg 2000 87 236 242 10.1046/j.1365-2168. 2000.01360.x (Pubitemid 30088655)
3. Urokinase receptors are required for 5β1 integrin-mediated signaling in tumor cells. Wei Y, Tang CH, Kim Y, Robillard L, Zhang F, Kugler MC, Chapman HA, J Biol Chem 2007 282 3929 17145753
4. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Cancer Res 2003 63 4648 12907645
5. Clinical significance of urokinasetype plasminogen activator receptor (uPAR) expression in cancer. de Bock CE, Wang Y, Med Res Rev 2004 24 13 39 10.1002/med.10054 14595671 (Pubitemid 38018594)
6. Evolving role of uPA/uPAR system in human cancers. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH, Canc Treat Rev 2008 34 122 136 10.1016/j.ctrv.2007.10. 005
7. The role of plasminogen-plasmin system in cancer. Kwaan HC, McMahon B, Cancer Treat Res 2009 148 43 66 10.1007/978-0-387-79962-9-4 19377918
8. The urokinasetype plasminogen activator system in cancer metastasis: a review. Andreasen PA, Kjøller L, Christensen L, Duffy MJ, Int J Cancer 1997 72 1 22 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z 9212216 (Pubitemid 27314632)
9. The microenvironment of the tumour-host interface. Liotta LA, Kohn EC, Nature 2001 411 375 379 10.1038/35077241 11357145 (Pubitemid 32467047)
10. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Plebani M, Herszènyi L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F, Clin Exp Metastasis 1997 15 418 426 10.1023/A:1018454305889 9219730 (Pubitemid 27285815)
11. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (cmet), autocrine motility factor receptor, and urokinasetype plasminogen activator receptor. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T, Miwa K, Endo Y, Yamamoto H, Watanabe H, Cancer 1998 82 2112 2122 10.1002/(SICI)1097-0142(19980601)82: 11<2112::AID-CNCR5>3.0.CO;2-X 9610690 (Pubitemid 28240817)
12. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK, Kim HS, Oncology 2004 66 210 217 10.1159/000077997 15218312 (Pubitemid 38813048)
13. Urokinasetype plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S, Cancer Sci 2003 94 43 49 10.1111/j.1349-7006.2003.tb01350. x 12708473 (Pubitemid 36575857)
14. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases. Kita Y, Fukagawa T, Mimori K, Kosaka Y, Ishikawa K, Aikou T, Natsugoe S, Sasako M, Mori M, Bri J Cancer 2008 100 153 159
15. Identification of proteins differentially expressed in gastric cancer cells with high metastatic potential for invasion to lymph nodes. Lee DH, Lee Y, Ryu J, Park SG, Cho S, Lee JJ, Choi C, Park BC, Mol Cells 2011 31 583 571
16. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. Zhang L, Zhao ZS, Ru GQ, Ma J, World J Gastroenterol 2006 12 3970 16810742
17. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y, Sasaki T, Virchows Arch 1996 427 487 496 8624578 (Pubitemid 126828180)
18. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, Kayahara M, Shimizu K, Ohta T, Miwa K, Endoscopy 2002 34 569 574 10.1055/s-2002-33228 12170412 (Pubitemid 34712002)
19. Prediction of peritoneal micrometastasis by peritoneal lavaged cytology and reverse transcriptase-polymerase chain reaction for matrix metalloproteinase-7 mRNA. Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T, Kinoshita K, Endo Y, Sugiyama K, Sasaki T, Clin Cancer Res 2001 7 1647 1653 11410502 (Pubitemid 32708631)
20. Investigation of serum tumor markers in the diagnosis of gastric cancer. Fan B, Xiong B, Hepato-gastroenterol 2011 58 239
21. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M, Adv Ther 2008 25 1075 1084 10.1007/s12325-008-0100-4 18821070
22. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brünner N, Clin Exp Metastasis 1996 14 297 307 8674284 (Pubitemid 26246575)
23. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38 mitogen-activated protein kinase activity. Huang S, New L, Pan Z, Han J, Nemerow GR, J Biol Chem 2000 275 12266 12272 10.1074/jbc.275.16.12266 10766865 (Pubitemid 30237807)
24. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. Hsiao JK, Law B, Weissleder R, Tung CH, J Biomed Optics 2006 11 034013 10.1117/1.2204029 (Pubitemid 44363246)
25. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Duffy M, Duggan C, Clin Biochem 2004 37 541 548 10.1016/j.clinbiochem.2004.05.013 15234235 (Pubitemid 38845017)
26. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor-and scatter factor-stimulated invasion of carcinoma cells. Rosenthal EL, Johnson TM, Allen ED, Apel IJ, Punturieri A, Weiss SJ, Cancer Res 1998 58 5221 9823336
27. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. Heiss MM, Simon EH, Beyer BCM, Gruetzner KU, Tarabichi A, Babic R, Schildberg FW, Allgayer H, J Clin Oncol 2002 20 2005 2016 10.1200/JCO.2002.08.003 11956259 (Pubitemid 34408789)
28. Prognostic impact of stromal cellderived urokinase-type plasminogen activator in gastric carcinoma. Okusa Y, Ichikura T, Mochizuki H, Cancer 1999 85 1033 1038 10.1002/(SICI)1097-0142(19990301)85:5<1033::AID-CNCR4>3.0.CO;2- K 10091785 (Pubitemid 29115580)
29. Axis of evil: molecular mechanisms of cancer metastasis. Bogenrieder T, Herlyn M, Oncogene 2003 22 6524 6536 10.1038/sj.onc.1206757 14528277 (Pubitemid 37372332)
30. Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy. Saldanha RG, Molloy MP, Bdeir K, Cines DB, Song X, Uitto PM, Weinreb PH, Violette SM, Baker MS, J Proteome Res 2007 6 1016 1028 10.1021/pr060518n 17330942 (Pubitemid 46480466)